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Abstract: The involuntary dual control systems of the autonomic nervous system (ANS) in 
the bladder of awake spontaneously hypertensive rats (SHRs) were investigated through 
simultaneous registrations of intravesical and intraabdominal pressures to observe detrusor 
overactivity (DO) objectively as a core symptom of an overactive bladder. SHRs (n = 6) 
showed the features of overactive bladder syndrome during urodynamic study, especially 
DO  during  the  filling  phase.  After  injection  of  the  nonselective  sympathetic  blocking  
agent labetalol, DO disappeared in 3 of 6 SHRs (50%). DO frequency decreased from  
0.98  ±   0.22  min
−1  to  0.28  ±   0.19  min
−1  (p  <  0.01),  and  DO  pressure  decreased  from  
3.82  ±   0.57  cm  H2O  to  1.90  ±   0.86  cm  H2O  (p  <  0.05).  This  suggests  that  the  DO 
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originating  from  the  overactive  parasympathetic  nervous  system  is  attenuated  by  the 
nonselective blocking of the sympathetic nervous system. The detailed mechanism behind 
this result is still not known, but parasympathetic overactivity seems to require overactive 
sympathetic nervous system activity in a kind of balance between these two systems. These 
findings are consistent with recent clinical findings suggesting that patients with idiopathic 
overactive bladder may have ANS dysfunction, particularly a sympathetic dysfunction. The 
search for newer and better drugs than the current anticholinergic drugs as the mainstay for 
overactive  bladder  will  be  fueled  by  our  research  on  these  sympathetic  mechanisms. 
Further studies of this principle are required.  
Keywords: autonomic nervous system; detrusor overactivity; labetalol 
 
1. Introduction 
Overactive bladder (OAB) is a bothersome medical condition that is defined by the core symptom 
of urinary urgency [1]. Urodynamic studies in humans have shown that this urinary urgency results 
from sudden, involuntary detrusor contraction during the filling phase of urination [2]. Overactive 
bladder is a highly prevalent health problem worldwide with an incidence that ranges from 16% to 
17% in the general population [3]. The age-specific prevalence of OAB is similar among men and 
women [4]. Overactive bladder has as meaningful negative impacts on health-related quality of life as 
other chronic diseases, such as diabetes and hypertension, do [5]. Although recent advances in our 
understanding  of  OAB  pathophysiology  have  led  to  improved  treatment  options,  the  current  drug 
therapy is still far from optimal because many aspects of the pathophysiology of OAB are not yet 
completely understood.  
The normal functions of the bladder are mainly under the involuntary control of the autonomic 
nervous system (ANS), although this involuntary control is mixed with some voluntary control of 
somatic nerves. The involuntary control derives from a dual set of control systems of sympathetic and 
parasympathetic nerves that generally work in opposition in their effect on target organs [6]. In the 
bladder, the neural control depends on appropriate changes in the balance between the sympathetic and 
the parasympathetic nervous systems through the filling and voiding phases [7]. Recently, trials in 
humans  have  proved  that  autonomic  dysfunction  is  involved  in  the  pathogenesis  of  OAB  [8–11]. 
Because the parasympathetic nervous system is responsible for the detrusor contraction, the detrusor 
overactivity (DO) in OAB represents overactive parasympathetic activity. However, it has remained 
unknown  whether  sympathetic  activity,  the  opposing  partner  in  bladder  function,  is  increased  or 
decreased during DO in patients with OAB. 
Thus, the present study was undertaken to compare bladder function and some characteristics of DO 
during the filling phase before and after the administration of the nonselective sympathetic blocking 
agent  labetalol.  For  this  purpose,  the  intraabdominal  and  intravesical  pressures  were  measured 
simultaneously in spontaneously hypertensive rats (SHRs), which are a model system for studying DO 
and altered sympathetic activity. The study also aimed to test the hypothesis that the dual-control Int. J. Mol. Sci. 2012, 13  5050 
 
 
systems  of  the  ANS  are  closely  related  and  that  upregulated  sympathetic  activity  is  required  to 
maintain the parasympathetic overactivity representative of DO in SHRs.  
2. Results and Discussion 
2.1. Results 
2.1.1. Body and Bladder Weights, Normalized Ratios between Them, and Systemic Blood Pressure 
SHRs were significantly lighter than Wistar rats (348.30 ±  7.03 and 390.00 ±  4.28 g, respectively). 
The bladder weights of SHRs were also significantly less than those of Wistar rats (1.08 ±  0.04 and 
1.96 ±  0.11 mg, respectively). When bladder weight (mg) was normalized to body weight (g), the ratio 
was significantly lower by 38.0% in SHRs than in Wistar rats (Figure 1A).  
Figure 1. Ratio of bladder weight to body weight (A) and effects of intraarterial labetalol 
(5 mg· kg
−1) on mean arterial blood pressure (B) in conscious Wistar and spontaneously 
hypertensive rats (SHRs). The ratio of bladder weight to body weight was significantly 
lower in SHRs than in Wistar rats.  The mean arterial pressures (time-averaged arterial 
pressure  over  10  min)  of  SHRs  were  significantly  higher  than  those  of  Wistar  rats  
(p < 0.01). After labetalol injection, mean arterial pressures decreased in both rats. Results 
are expressed as mean ±  standard error of the mean. * p < 0.05, ** p < 0.01, *** p < 0.001 
(unpaired Student’s t-test).  
 
The mean arterial pressure (time-averaged arterial pressure over 10 min) was significantly different 
between  Wistar  rats  (111.0  ±   32.0  SE  cm  H2O)  and  SHRs  (233.0  ±  4.7  SE  cm  H2O)  
(p < 0.01). After the injection of labetalol, mean arterial pressures decreased to 89.4 ±  25.6 SE cm H2O  
(p < 0.001) in Wistar rats and 163.1 ±  4.7 SE cm H2O (p < 0.05) in SHRs, respectively. Even after Int. J. Mol. Sci. 2012, 13  5051 
 
 
labetalol  injection,  mean  arterial  pressure  differed  significantly  between  the  groups  (p  <  0.05)  
(Figure 1B).  
2.1.2. Cystometric Parameters before and after the Intraarterial Injection of Labetalol  
Representative cystometric tracings from Wistar rats and SHRs before and after the injection of 
labetalol are shown in Figure 2. All curves of the micturition cycles with arterial blood pressures were 
reproducibly recorded in all animals, and the comparisons of all pressure parameters were performed 
on the basis of detrusor pressure, which was defined as the difference between IVP and IAP. Before 
the injection of labetalol, there were no significant differences in BP, FP, or TP between Wistar rats 
and  SHRs  (Figure  3A–C).  However,  MP  was  significantly  higher  in  SHRs  than  in  Wistar  rats  
(Figure 3D). After intraarterial injection of labetalol, the SHRs showed decreased values in only FP  
(p < 0.05) and TP (p < 0.05), whereas the Wistar rats showed no changes in any of the pressure 
parameters (Figures 3,4). After the injection of labetalol, there were no significant differences between 
the Wistar rats and the SHRs in any pressure parameters except MP. All volume parameters, including 
BC (p < 0.001), MV (p < 0.001), RV (p < 0.05), and MI (p < 0.001), were lower in SHRs than in 
Wistar rats before the injection of labetalol. Labetalol injection did not change any volume parameters 
in either group. After labetalol injection, all volume parameters were still significantly lower in SHRs 
than in Wistar rats (Figure 5). Before the injection of labetalol, DO proved by IAP was not shown in 
Wistar rats, but it was shown in all SHRs. After the injection of labetalol, DO disappeared in 3 of  
6  SHRs  (50%)  (Figure  6A).  In  addition,  DO  frequency  decreased  from  0.98  ±   0.22  min
−1  to  
0.28 ±  0.19 min
−1 (p < 0.01), and DO pressure decreased from 3.82 ±  0.57 cm H2O to 1.90 ±  0.86 cm 
H2O (p < 0.05) (Figure 6B).  
Figure  2.  Representative  cystometrogram  showing  simultaneous  arterial  pressures, 
detrusor  pressures,  and  micturition  volume  before  and  after  the  arterial  injection  of  
5 mg· kg
−1 labetalol in conscious SHRs (A) and Wistar rats (B). Pr: pressure; DP: detrusor 
pressure; Vol: volume.  
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Figure 3. The effects of intraarterial 5 mg· kg
−1 labetalol on the pressure parameters in 
SHRs and Wistar rats. (A) Basal pressure by detrusor pressure (DP); (B) Flow pressure; (C) 
Threshold pressure by DP; (D) Micturition pressure by DP. Results are expressed as mean 
±   standard  error  of  the  mean.  *  p  <  0.05,  **  p  <  0.01  (unpaired  Student’s  t-test).  
NS: not significant.  
 
Figure  4.  Representative  cystometrogram  showing  simultaneous  arterial  pressures  and 
flow  pressure  by  detrusor  pressure  before  and  after  the  arterial  injection  of  5  mg· kg
−1 
labetalol in conscious SHRs. DP: detrusor pressure; Pr: pressure.  
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Figure  5. The effects of intraarterial  5 mg· kg
−1 labetalol on the volume parameters in 
SHRs and Wistar rats. (A) Bladder capacity; (B) Micturition volume; (C) Residual volume; 
(D)  Micturition  interval.  Results  are  expressed  as  mean  ±   standard  error  of  the  mean.  
* p < 0.05, ** p < 0.01, *** p < 0.001 (unpaired Student’s t-test). NS: not significant. 
 
Figure  6.  The  effects  of  intraarterial  5  mg· kg
−1  labetalol  on  the  cystometric  detrusor 
overactivity (DO)-related parameters during the filling phase in SHRs  and Wistar rats.  
(A) DO occurrence rate; (B) DO frequency and pressure. Before the injection of labetalol, 
DO proved by IAP was shown in all SHRs. After the injection of labetalol, DO disappeared 
in  3  of  6  SHRs.  Also,  DO  frequency  and  pressure  decreased  significantly.  Results  
are expressed as mean ±  standard error of the mean. * p < 0.05, ** p < 0.01 (unpaired 
Student’s t-test).  
 
2.2. Discussion 
The  results  of  the  present  study  showed  that  intraarterial  labetalol,  a  nonselective  sympathetic 
blocking agent, objectively decreased the occurrence, frequency, and pressure of DO in SHRs with a Int. J. Mol. Sci. 2012, 13  5054 
 
 
lowering  of  systemic  blood  pressure.  This  suggests  that  the  DO  originating  from  the  overactive 
parasympathetic  nervous  system  is  attenuated  by  the  nonselective  blocking  of  the  overactive 
sympathetic nervous system, which is a major characteristic of SHRs. The detailed mechanism of this 
result remains unknown, but parasympathetic overactivity seems to require overactive sympathetic 
nervous system activity in a kind of balance between the two systems. Furthermore, this finding is 
consistent  with  the  recent  clinical  findings  that  patients  with  idiopathic  OAB  may  have  ANS 
dysfunction, particularly sympathetic dysfunction.  
The  human  nervous  system  is  a  network  within  which  the  ANS  plays  an  important  role  in 
controlling the many vital functions of visceral organs, such as heart rate, respiration rate, digestion, 
and micturition, both automatically and involuntarily. This innervation is divided into the sympathetic 
and  the  parasympathetic  nervous  systems,  which  usually  work  in  opposition  to  each  other  [7]. 
Anatomically, each of the systems has a different origin located between the central nervous system 
and the target organs, such as from the thoracic and lumbar spinal cord in the sympathetic nervous 
system and from the craniosacral spinal cord in the parasympathetic nervous system. The two systems 
also  have  a  unique  sequential  two-neuron  efferent  pathway,  in  which  the  preganglionic  neuron 
synapses onto a postganglionic neuron before reaching the target organ, but the innervations vary 
according to the functions of the target organs [6,12]. Thus, the anatomical arrangements of the ANS 
are so complex, nuanced, and unique that it is impossible to draw any grounded conclusions about the 
normal functions of the ANS and how much ―normal‖ is changed in various disease states.  
Despite the expected important role of the ANS in OAB, few studies have examined the exact role 
of the ANS in the pathophysiology of OAB because of difficulties in methodology. However, growing 
evidence suggests that an imbalance between the sympathetic and parasympathetic activity of the ANS 
is  involved  in  the  pathophysiology  of  OAB  [8,9,11].  Some  epidemiologic  studies  in  men  with 
symptomatic benign prostatic hyperplasia have suggested that those symptoms may be closely related 
to sympathetic overactivity. For example, McVary et al. showed that validated measures of hyperactive 
ANS activity are significantly related to the most commonly used symptom scores in men with benign 
prostatic hyperplasia [13]. Kim et al. proved that female incontinent patients with urodynamic DO 
have sympathetic overactivity compared with parasympathetic activity as assessed through a frequency 
domain analysis on a heart rate variability test [11].  
Previous studies using animal models such as SHRs also support a link between ANS hyperactivity 
and urodynamic voiding parameters [14,15], which agrees with our current results. SHRs, which were 
previously proved to have an overabundance of sympathetic nerve fibers innervating the bladder [16], 
void more frequently and have a smaller bladder capacity and higher maximal pressure with higher 
blood pressures during voiding than do control rats. Flow pressure, which was proved in our previous 
study [17], represents the urethral resistance to voiding, because the pressure is at the time of the start 
of flow of urine. In the current study, this pressure decreased as a result of the decreased internal 
sphincter activity after the global blocking of sympathetic activity.  
Our  ultimate  success  in  controlling  DO  is  still  hampered  by  our  incomplete  knowledge  of  the 
mechanisms  of  DO.  Most  previous  studies  have  focused  on  etiological  and  pathophysiological 
mechanisms inside the bladder, such as muscarinic receptors or gap junctions [5,6], and few studies 
have explored mechanisms beyond the bladder, especially the ANS. Theoretically, parasympathetic 
stimulation through the pelvic nerve induces detrusor contraction, whereas sympathetic stimulation Int. J. Mol. Sci. 2012, 13  5055 
 
 
through the hypogastric nerve induces detrusor relaxation and internal sphincter contraction. Normally 
during the storage phase, the parasympathetic signals to the bladder are suppressed by tonic inhibitory 
systems in the brain and the sympathetic pathways are activated by the spinal reflex [12]. However, 
patients with idiopathic OAB show increased parasympathetic activity during the filling phase [18]. 
Normally, both components of the ANS are in constant balance. If one is stronger, the other becomes 
stronger  to  compensate.  Thus,  the  sympathetic  activity  in  OAB  may  be  stronger  than  that  in  the  
normal state.  
In the current study, SHRs showed DO and high blood pressure. After global blocking of sympathetic 
activity, both the frequency and the pressure of DO were decreased with a lowering of blood pressure. 
Thus, the parasympathetic activity inducing DO via the spinal pathway seems to require the backup of 
sympathetic activity. Further studies are warranted to define the underlying mechanisms.  
3. Experimental Section  
3.1. Animals 
Age-matched (14-week-old) 6 male SHRs and normotensive control 6 female Wistar/ST (Wistar) 
rats (Japan SLC, Hammatsu, Japan) weighing 200 to 250 g were used in this study. They were reared 
in our laboratory under controlled conditions with 12 h of light and 12 h of darkness and were allowed 
free access to standard food pellets and tap water. All experimental animal procedures were performed 
in accordance with the Guide for the Care and Use of Laboratory Animals of the National Institutes of 
Health and were approved by the local animal ethics committee.  
3.2. Surgical Procedures 
Implantations of the catheters for the recordings of intravesical pressure (IVP) and intraabdominal 
pressure (IAP) and drug injection were performed as described previously [19]. In brief, the rats were 
anaesthetized  with  ketamine  (75  mg/kg  intraperitoneally;  Ketamine,  Yuhan,  Seoul,  Korea)  and 
xylazine (15 mg/kg intraperitoneally; Rompun,  Bayer Korea Ltd, Seoul, Korea). Through a lower 
midline incision, a polyethylene catheter (PE-50; Becton Dickinson, Parsippany, NJ, USA) with a cuff 
was inserted into the dome of the bladder. To record IAP, a balloon (Latex, Dawoo Medical, Incheon, 
Korea) around the cuff of a catheter tip was placed proximal to the bladder and was tied to the other 
catheter to the bladder with silk tie. To record systemic arterial pressure, a catheter (PE-10; Becton 
Dickinson) was inserted into the lower abdominal aorta via the femoral artery. The catheters were tunneled 
subcutaneously and exited through the skin at the back of the animal. The free ends of the catheters 
were sealed. After surgery, each rat was caged individually and maintained in the same manner.  
3.3. In Vivo Cystometric Investigations and Analysis 
Three days after the catheter implantations, mean arterial pressures were measured for about 10 min 
before  and  after  the  injection  of  labetalol  in  animals  that  were  allowed  to  roam  freely  in  the  
cage [20,21]. Labetalol (labetalol hydrochloride; 5 mg· kg
−1) was injected through the catheter into the 
lower abdominal aorta. Before the cystometry, body weight was recorded. Cystometrograms were then 
obtained  in  unanaesthetized,  unrestrained  rats  in  metabolic  cages.  The  indwelling  catheter  to  the Int. J. Mol. Sci. 2012, 13  5056 
 
 
bladder was connected to a two-way valve that was connected via a T-tube to a pressure transducer 
(Research  Grade  Blood  Pressure  Transducer,  Harvard  Apparatus,  Holliston,  MA,  USA)  and  a 
microinjection pump (PHD22/2000 pump, Harvard Apparatus). The other indwelling catheters, which 
were connected to an air-free abdominal balloon and the femoral artery, were connected to another 
pressure transducer to record the IAP. The balloon functions best when it is filled and stabilized to 
around 50 to 100 cm H2O of IAP. To prevent IAP and blood pressure decay by minute leakages 
through the multiple joints of the lines and connectors, Parafilm M laboratory sealing film (American 
National Can, Chicago, IL, USA) was wrapped around the joints. Micturition volumes were recorded 
by means of a fluid collector connected to a force-displacement transducer (Research Grade Isometric 
Transducer). Room-temperature saline was infused into the bladder continuously at a rate of 10 mL· h
−1. 
IVP, IAP, and micturition volumes were recorded continuously with Acq Knowledge 3.8.1 software 
and an MP150 data acquisition system (Biopac Systems Inc., Goleta, CA, USA) at a sampling rate of 
100 Hz. The mean values from three reproducible micturition cycles were used for evaluation. IAP 
was defined as the recorded balloon pressure corrected by subtracting the lowest balloon pressure in 
each  voiding  cycle,  which  is  comparable  to  zeroing  in  human  cystometry.  Detrusor  pressure  was 
defined as IVP minus IAP. The IVP rises during the filling phase were defined as increments of IVP 
that exceeded 2 cm H2O from baseline, which was interpreted as abdominal straining if occurring with 
simultaneous similar changes in IAP, or as DO if occurring without simultaneous similar changes in 
IAP [22]. Flow pressure (FP) was defined as the IVP or detrusor pressure at the time of the start of 
flow of urine from the urethra, which was detected by applying a small electric current to a circuit grid 
beneath the rat [17]. 
The following two kinds of cystometric parameters were investigated: 
•  Pressure- and volume-related parameters derived from detrusor pressure: Basal pressure (BP; 
the lowest bladder pressure during filling), FP (bladder pressure at the time of start of flow of urine 
from  the  urethra),  threshold  pressure  (TP;  bladder  pressure  immediately  before  micturition), 
maximum  pressure  (MP;  maximum  bladder  pressure  during  the  micturition  cycle),  micturition 
volume (MV; volume of expelled urine), residual volume (RV; remaining urine after voiding), 
bladder  capacity  (BC;  MV +  RV), and micturition  interval  (MI;  intervals  between micturition 
contractions).  
•  DO-related parameters during the filling phase: Time of filling phase (interval from the initiation 
of  infusion  through  the  tube  and  the  point  immediately  before  the  initiation  of  micturition), 
frequency  of  abdominal  straining  per  minute,  frequency  of  DO  per  minute,  and  increased 
amplitude from base to peak of DO spike as IVP. These frequencies were calculated on the basis of 
the time of filling phase.  
After cystometry, the animals were sacrificed by cervical dislocation. The bladder and urethra were 
removed en bloc and separated at the level of the bladder neck and the bladder was weighed.  
3.4. Statistical Analyses 
The results are expressed as mean values ±  standard errors of the mean. Normal distributions were 
confirmed by the Shapiro-Wilks’ W test. Statistical analyses were undertaken with unpaired Student’s Int. J. Mol. Sci. 2012, 13  5057 
 
 
t-tests or a one-way analysis of variance with the Tukey post-hoc test for multiple comparisons. The 
data for  DO incidence were expressed as percentages of animals showing DO.  All analyses  were 
performed with GraphPad Prism, version 5.03, 2009 (GraphPad Software Inc., La Jolla, CA, USA).  
p < 0.05 was considered statistically significant. 
4. Conclusions  
We  demonstrated  herein  that  intraarterial  labetalol,  a  nonselective  sympathetic  blocking  agent, 
suppresses the occurrence, frequency, and pressure of DO in SHRs. This suggests that the DO from the 
overactive  parasympathetic  nervous  system  requires  compensatory  overactive  sympathetic  nervous 
system activity in a kind of balance between these two systems. The current mainstay of pharmacological 
therapies for OAB is still anticholinergic drugs [23], which suppress the overactive parasympathetic 
nervous system during the filling phase. These competitive inhibitors of acetylcholine have no significant 
effect on voiding because there is a massive release of acetylcholine during voiding compared with 
during the storage phase. However, these drugs can produce voiding difficulty or urinary retention in 
clinical practice, especially in patients with benign prostatic hyperplasia. The search for newer and 
better drugs will be fueled by our research on the mechanisms of sympathetic nervous system activity. 
Further studies of this principle are required.  
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